Maxtec’s MaxO2 ME+p oxygen monitor with integrated pressure monitoring has received FDA clearance and is now available for purchase in the United States, according to a product launch announcement from Perma Pure Group (Maxtec and Perma Pure).
The MaxO2 ME+p is intended for continuous monitoring of the concentration of oxygen and pressure being delivered to patients ranging from newborns to adults. In addition, the device can serve as a useful tool to integrate into a bubble CPAP therapy setup for use in a NICU setting.
By providing real-time, accurate data on oxygen concentration and pressure, the MaxO2 ME+p helps healthcare providers ensure that their patients are receiving the correct therapy, the company says.
“We are thrilled to introduce the MaxO2 ME+p to the market,” said Kathy Ouellette, President and CEO of Perma Pure Group. “This device is the result of our ongoing commitment to developing innovative medical devices that make a real difference in the lives of patients and healthcare providers. We believe that the MaxO2 ME+p is a game-changer in the field, and we are excited to see the impact it will have on patient care.”
More information about the MaxO2 ME+p is available on Maxtec’s website.
